expected total cumulative dose received. Objective response rate (CR+PR) in the entire cohort was 66%. Median progression-free survival (PFS) from start of alternate schedule is 17.1 months (95% CI 5.2not reached). 6-month PFS is 65% (95% CI 46%-79%) starting from when alternate schedule of Nivo was begun. We will present updated toxicity and treatment outcomes in the meeting. Conclusion: Nivolumab 240mg administered at q 4 weeks or longer is feasible. Further investigation is needed to optimize patient selection for alternate dosing schedule.
Background: Long survivors (LS) in non-small-cell lung cancer (NSCLC), defined as an overall survival (OS) greater than 2 years, are less than 10% in most series. Classical prognosis factors include stage, weight loss and ECOG, but there are other factors whose influence on the evolution of these patients is uncertain. Recently, different drugs targeted against EGFR, ALK and ROS 1 reach OS longer than 2 years in a limited number of patients (less than 20%). Immunotherapy in NSCLC has demonstrated very promising results with more LS compared to chemotherapy in first and second line setting. In this study, we have focused in the analysis of LS patients with advanced NSCLC EGFR wt (wild type) and ALK nt (non-translocated), defined as those with OS greater than 36 months, in 8 hospitals in Madrid. Method: In this serie, first of all, we will try to make a clinical, histopathological and immunological characterization collecting data from clinical reports according to a previously defined information. In a second step, we will carry out a genetic analysis of these patient samples comparing to an opposite extreme short survivors (SS) samples (OS less than 9 months) from same centers. We used a NGS method of RNA-seq technology with the idea of identify differentiating profiles of gene expression between the two opposite populations with a later confirmation by RT-PCR in the rest of the tissue samples and liquid biopsy. Result: We have obtained a differential transcriptome expression between samples from 6 LS and 6 SS, resulting 13 overexpressed and 42 under-expressed genes in LS comparing to SS transcriptome expression. Some of the genes involved in this profile belong to different families and cellular pathways: Secretin receptor, Surfactant Protein, Trefoil Factor 1, Serpin Family, Ca bindings protein channel and Toll like Receptor family. A further confirmation of this profile is carrying on by RT-PCR in the rest of the samples and liquid biopsy from the rest of the patients included in the study. Conclusion: We present the first data from a genetic analysis of a LS population with NSCLC EGFR wt (wild type) and ALK nt (non-translocated), obtaining a differential RNA profile Keywords: long survivors, non small cell lung cancer P3.01-89 Upfront Surgery Versus Neoadjuvant Treatment Followed by Surgery in Pathologic N2 Non-Small Cell Lung Cancer
